2seventy bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 274
- Market Cap
- $235.3M
- Website
- http://www.2seventybio.com
- Introduction
2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1
Recruiting
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Biological: bbT369
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- 2seventy bio
- Target Recruit Count
- 50
- Registration Number
- NCT05169489
- Locations
- 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Study of bb21217 in Multiple Myeloma
Phase 1
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Biological: bb21217
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- 2seventy bio
- Target Recruit Count
- 72
- Registration Number
- NCT03274219
- Locations
- 🇺🇸
Winship Cancer Insitute, Emory University, Atlanta, Georgia, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath